Chain Drug Review media bias and reliability
Chain Drug Review is held by the ratings provider we draw on, and no rater has placed it on the political spectrum. We have seen it on 4 published stories of ours.
The short answers
Is Chain Drug Review biased?
Chain Drug Review is held by the ratings provider we draw on, and no rater has placed it on the political spectrum. An outlet rating describes a broad pattern in its output, not every article it publishes.
Is Chain Drug Review left or right?
Chain Drug Review is held by the ratings provider we draw on, and no rater has placed it on the political spectrum.
Is Chain Drug Review reliable?
We do not hold a factual-reliability assessment for Chain Drug Review. A political-leaning label would not answer that question on its own, so we do not infer reliability from left, centre or right.
What Chain Drug Review has been covering
Our account of each story, written from every outlet that ran it, with Chain Drug Review’s own report linked underneath.
The Weston family's holding company, Wittington Investments, has agreed to purchase the UK pharmacy chain Boots for approximately £6.7 billion. The deal includes Boots' retail operations in the UK and Ireland, Boots Opticians, and the No7 Beauty Company.
Chain Drug Review reported it asWeston family's Wittington buys Boots for $8.9 billion (opens Chain Drug Review in a new tab)
Bayer will invest $2.2 billion in a new pharmaceutical manufacturing site in New Albany, Ohio, creating approximately 600 high-value jobs and 1,500 construction jobs. The facility is expected to be operational in phases starting in 2031.
Chain Drug Review reported it asBayer to build $2.2 billion pharmaceutical plant in Ohio (opens Chain Drug Review in a new tab)
Former US House Majority Leader Eric Cantor has been appointed president and CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA). The appointment comes as the industry faces pressure over drug prices.
Chain Drug Review reported it asPhRMA selects Eric Cantor to lead organization as next president and CEO (opens Chain Drug Review in a new tab)
The Trump administration announced new drug pricing agreements with nine pharmaceutical companies. These deals are intended to align U.S. prices with those paid in other developed countries, impacting state Medicaid programs.
Chain Drug Review reported it asNine more drugmakers join Trump Administration’s MFN Drug Pricing Program (opens Chain Drug Review in a new tab)
Who says so
No rating organisation we draw on has placed Chain Drug Review. We asked on 10 October 2026.
How reliably it reports fact
A rating of the newsroom in general, by others, and a different thing from the Trust score we publish on each story, which judges one piece of reporting.
We hold no factual-reliability rating for this outlet.
Who owns it
We hold no ownership record for Chain Drug Review.
Where it publishes from
- Official site
- chaindrugreview.com
- Seen publishing on
- chaindrugreview.com
- Access
- Free to read
What we have seen ourselves
Counted across the stories this site has published, which is the only denominator a reader can check: every one of them has a page, and every page lists the reports it was written from.
- Stories
- 4
- Reports listed
- 4
- We could read
- 0
- First seen
- 7 August 2026
4 of those reports were paywalled or blocked to us. Our reading of this outlet is built on the 0 we could open, not on everything it published.
A blindspot is measured against one side of the spectrum. Chain Drug Review has not been placed on the spectrum, so there is no side to count against and we publish no figure here.
Across the 4 stories of ours where at least three of the reports we listed carried a time, another outlet was always ahead of Chain Drug Review: its report arrived a median of 19 hours after the earliest one we logged.
Measured 18 October 2026. Last seen in a coverage list 13 October 2026. Ratings pulled 10 October 2026.
Think this page is wrong?
The leanings above are published by AllSides, Ad Fontes Media and Media Bias/Fact Check, and we republish them rather than make them. If you think one is misapplied, the strongest place to say so is with the organisation that made it, and every verdict here links to their page.
What we are responsible for is everything else: the ownership chain, where Chain Drug Review publishes from, which of our stories we have listed it on, and whether we have the right publisher at all. Tell us what is wrong and an editor reads it.
Report something wrong on this page
Anything we correct is written up in the public corrections log. We do not publish reader votes as a rating, because an unattributed rating is the thing this site exists to argue against.
Every rating on this page is a named third party’s published work, republished with its author and, where one exists, a link to it. Our own coverage record is the section we measure ourselves. Neither is a judgement of any individual report: those are scored story by story, and the reasoning is on our methodology page.